LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.

    Balgi, Aruna D / Fonseca, Bruno D / Donohue, Elizabeth / Tsang, Trevor C F / Lajoie, Patrick / Proud, Christopher G / Nabi, Ivan R / Roberge, Michel

    PloS one

    2009  Volume 4, Issue 9, Page(s) e7124

    Abstract: ... that the four compounds stimulate autophagy and inhibit mTORC1 signaling in cells maintained in nutrient-rich ... can reversibly inhibit mTORC1 and stimulate autophagy should greatly facilitate the preclinical and clinical ... signaling and autophagy in human disease requires active chemicals with pharmacologically desirable ...

    Abstract Background: Mammalian target of rapamycin complex 1 (mTORC1) is a protein kinase that relays nutrient availability signals to control numerous cellular functions including autophagy, a process of cellular self-eating activated by nutrient depletion. Addressing the therapeutic potential of modulating mTORC1 signaling and autophagy in human disease requires active chemicals with pharmacologically desirable properties.
    Methodology/principal findings: Using an automated cell-based assay, we screened a collection of >3,500 chemicals and identified three approved drugs (perhexiline, niclosamide, amiodarone) and one pharmacological reagent (rottlerin) capable of rapidly increasing autophagosome content. Biochemical assays showed that the four compounds stimulate autophagy and inhibit mTORC1 signaling in cells maintained in nutrient-rich conditions. The compounds did not inhibit mTORC2, which also contains mTOR as a catalytic subunit, suggesting that they do not inhibit mTOR catalytic activity but rather inhibit signaling to mTORC1. mTORC1 inhibition and autophagosome accumulation induced by perhexiline, niclosamide or rottlerin were rapidly reversed upon drug withdrawal whereas amiodarone inhibited mTORC1 essentially irreversibly. TSC2, a negative regulator of mTORC1, was required for inhibition of mTORC1 signaling by rottlerin but not for mTORC1 inhibition by perhexiline, niclosamide and amiodarone. Transient exposure of immortalized mouse embryo fibroblasts to these drugs was not toxic in nutrient-rich conditions but led to rapid cell death by apoptosis in starvation conditions, by a mechanism determined in large part by the tuberous sclerosis complex protein TSC2, an upstream regulator of mTORC1. By contrast, transient exposure to the mTORC1 inhibitor rapamycin caused essentially irreversible mTORC1 inhibition, sustained inhibition of cell growth and no selective cell killing in starvation.
    Conclusion/significance: The observation that drugs already approved for human use can reversibly inhibit mTORC1 and stimulate autophagy should greatly facilitate the preclinical and clinical testing of mTORC1 inhibition for indications such as tuberous sclerosis, diabetes, cardiovascular disease and cancer.
    MeSH term(s) Acetophenones/pharmacology ; Amiodarone/pharmacology ; Antinematodal Agents/pharmacology ; Automation ; Autophagy/drug effects ; Autophagy/physiology ; Benzopyrans/pharmacology ; Cardiovascular Agents/pharmacology ; Drug Evaluation, Preclinical/methods ; Enzyme Inhibitors/pharmacology ; Humans ; Mechanistic Target of Rapamycin Complex 1 ; Models, Chemical ; Multiprotein Complexes ; Niclosamide/pharmacology ; Nutritional Sciences ; Perhexiline/pharmacology ; Proteins ; Signal Transduction/drug effects ; TOR Serine-Threonine Kinases ; Transcription Factors/antagonists & inhibitors ; Transcription Factors/metabolism
    Chemical Substances Acetophenones ; Antinematodal Agents ; Benzopyrans ; Cardiovascular Agents ; Enzyme Inhibitors ; Multiprotein Complexes ; Proteins ; Transcription Factors ; Niclosamide (8KK8CQ2K8G) ; rottlerin (E29LP3ZMUH) ; TOR Serine-Threonine Kinases (EC 2.7.1.1) ; Mechanistic Target of Rapamycin Complex 1 (EC 2.7.11.1) ; Perhexiline (KU65374X44) ; Amiodarone (N3RQ532IUT)
    Language English
    Publishing date 2009-09-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0007124
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.

    Aruna D Balgi / Bruno D Fonseca / Elizabeth Donohue / Trevor C F Tsang / Patrick Lajoie / Christopher G Proud / Ivan R Nabi / Michel Roberge

    PLoS ONE, Vol 4, Iss 9, p e

    2009  Volume 7124

    Abstract: ... that the four compounds stimulate autophagy and inhibit mTORC1 signaling in cells maintained in nutrient-rich ... signaling and autophagy in human disease requires active chemicals with pharmacologically desirable ... that they do not inhibit mTOR catalytic activity but rather inhibit signaling to mTORC1. mTORC1 inhibition and ...

    Abstract BACKGROUND:Mammalian target of rapamycin complex 1 (mTORC1) is a protein kinase that relays nutrient availability signals to control numerous cellular functions including autophagy, a process of cellular self-eating activated by nutrient depletion. Addressing the therapeutic potential of modulating mTORC1 signaling and autophagy in human disease requires active chemicals with pharmacologically desirable properties. METHODOLOGY/PRINCIPAL FINDINGS:Using an automated cell-based assay, we screened a collection of >3,500 chemicals and identified three approved drugs (perhexiline, niclosamide, amiodarone) and one pharmacological reagent (rottlerin) capable of rapidly increasing autophagosome content. Biochemical assays showed that the four compounds stimulate autophagy and inhibit mTORC1 signaling in cells maintained in nutrient-rich conditions. The compounds did not inhibit mTORC2, which also contains mTOR as a catalytic subunit, suggesting that they do not inhibit mTOR catalytic activity but rather inhibit signaling to mTORC1. mTORC1 inhibition and autophagosome accumulation induced by perhexiline, niclosamide or rottlerin were rapidly reversed upon drug withdrawal whereas amiodarone inhibited mTORC1 essentially irreversibly. TSC2, a negative regulator of mTORC1, was required for inhibition of mTORC1 signaling by rottlerin but not for mTORC1 inhibition by perhexiline, niclosamide and amiodarone. Transient exposure of immortalized mouse embryo fibroblasts to these drugs was not toxic in nutrient-rich conditions but led to rapid cell death by apoptosis in starvation conditions, by a mechanism determined in large part by the tuberous sclerosis complex protein TSC2, an upstream regulator of mTORC1. By contrast, transient exposure to the mTORC1 inhibitor rapamycin caused essentially irreversible mTORC1 inhibition, sustained inhibition of cell growth and no selective cell killing in starvation. CONCLUSION/SIGNIFICANCE:The observation that drugs already approved for human use can reversibly inhibit mTORC1 and stimulate ...
    Keywords Medicine ; R ; Science ; Q
    Subject code 500
    Language English
    Publishing date 2009-09-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top